Clinical trials
Completed Inflammatory Breast Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 5 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 9 |
| GBG Forschungs GmbH | 5 |
| City of Hope Medical Center | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Alliance for Clinical Trials in Oncology | 2 |
| Dana-Farber Cancer Institute | 2 |
| GlaxoSmithKline | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| M.D. Anderson Cancer Center | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammatory Breast Neoplasms | 54 |
| Breast Neoplasms | 45 |
| Breast Neoplasms, Male | 10 |
| Carcinoma, Ductal, Breast | 8 |
| Bile Duct Neoplasms | 3 |
| Carcinoma, Hepatocellular | 3 |
| Carcinoma, Lobular | 3 |
| Carcinoma, Medullary | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colonic Neoplasms | 3 |
Trials
Showing 51 to 54 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.